Etelcalcetide
Also referenced as: Parsabiv
A peptide calcimimetic used for secondary hyperparathyroidism in hemodialysis.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Parsabiv is FDA-approved for secondary hyperparathyroidism in adults with CKD on hemodialysis.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A peptide calcimimetic used for secondary hyperparathyroidism in hemodialysis.
Parsabiv is FDA-approved for secondary hyperparathyroidism in adults with CKD on hemodialysis.
It suppresses PTH rather than replacing it. Findings do not establish use for general CKD or primary hyperparathyroidism.
Why It's Being Studied
- Secondary hyperparathyroidism
- Calcium-sensing receptors
Mechanism of Action
Calcium-sensing-receptor activation suppresses parathyroid hormone secretion.
Calcium-sensing-receptor activation suppresses parathyroid hormone secretion. It suppresses PTH rather than replacing it. Findings do not establish use for general CKD or primary hyperparathyroidism.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Secondary hyperparathyroidism
- Calcium-sensing receptors
- Intravenous approved medicine during hemodialysis
Evidence Summary
Controlled human studies support PTH reduction in adults with CKD receiving hemodialysis.
Higher tiers carry more weight. Filled tiers have evidence for Etelcalcetide; tap to read it.
- Controlled human studies support PTH reduction in adults with CKD receiving hemodialysis.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Controlled human studies support PTH reduction in adults with CKD receiving hemodialysis.
Reported Adverse Events in Research
- Severe hypocalcemia can cause seizures and QT-related arrhythmias; excessive PTH suppression can contribute to adynamic bone disease.
Limitations of Current Evidence
- It suppresses PTH rather than replacing it. Findings do not establish use for general CKD or primary hyperparathyroidism.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Etelcalcetide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicine during hemodialysis | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Etelcalcetide — prescribing label